We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.875 | 5.75 | 6.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.31 | 6.76M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/4/2024 10:26 | AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEN | blackhorse23 | |
18/4/2024 08:56 | Patience rewards long term holders. The share price will shoot up between now and July 2024. | kingston78 | |
17/4/2024 10:13 | Thank you I will look. Just speculation then. | hazl | |
17/4/2024 09:34 | There is an ongoing chat on LSE. | batiatus | |
17/4/2024 09:20 | Batiatus....where did you hear talk of delist? Does somebody else want us on the cheap? | hazl | |
17/4/2024 08:58 | Now that is a good sign. | hazl | |
17/4/2024 08:57 | Thanks easily clickable. | hazl | |
16/4/2024 19:56 | New Director for Regulatory Affairs has joined from QuantuMDx...... hxxps://www.quantumd | indomie1 | |
16/4/2024 14:57 | Batiatus..I can believe that soon I hope | albert35911 | |
16/4/2024 12:55 | There are talks of delist which doesn't make sense for me. If the test kits are proven a success, wouldn't the NHS fund them on full recommendation? Eventually these kits can be commercialised and sold abroad (US and EU markets) I don't really understand why some are saying the test kits are not commercially viable. Remember the COVID-19 test kits costed £20 and they were just paper and swabs. | batiatus | |
16/4/2024 11:10 | Which leads the way hopefully to commercialisdation and profit. | hazl | |
16/4/2024 11:09 | This says it all really. Helping 'to get our really inspiring products through regulatory approvals and into clinical settings to help improve patient outcomes'. | hazl | |
16/4/2024 11:04 | An hour ago. genedrive plc @genedriveplc Welcome Caroline Alexander, our new Director of Quality Assurance and Regulatory Affairs, to the Genedrive team! We are grateful to have you on board and look forward to seeing your wealth of experience and knowledge in action! | hazl | |
16/4/2024 07:36 | Thank you Batiatus I had noticed your post but been busy elsewhere. | hazl | |
16/4/2024 07:35 | Well the hype out there! At least we cannot be accused of any of the criticisms here. Our tests are fairly black and white it seems. | hazl | |
14/4/2024 18:30 | "A world-first genetic test... Backed by £900,000 funding from the National Institute for Health Research... It is expected the test could save the NHS £5 million every year...." Some points taken from the NHS website found in the link below: hxxps://www.england. | batiatus | |
11/4/2024 14:11 | I have sent you a private message indomie in case you are working. | hazl | |
11/4/2024 11:52 | As we know we have patents. We are also considered as cutting edge with our preventative medicine label. 'The Genedrive® System is a point of care molecular diagnostics platform that can rapidly detect, pathogens or genetic variants aligned to clinical outcome. ' | hazl | |
11/4/2024 11:46 | Indomie for you. Alp knows a bit about this sort of thing. This is from the SHA bb 'Hazl asked a question about 'Point of Care Pharmacogenetic Testing' which is an often overlooked sector. The sector is expected to be around $9bn this year. I have posted on here as it may be of interest to others. Here is a good summary: Two additional comments that I would add: - the company has to have blocking IP to give the developer any value. - theoretically it can have a biggish impact on the sale of certain drugs. eg Simple example. If a drug has a 50% efficacy and is now given to those 50% of patients then either the price has to double or sales revenues will be half. I hope worth a read.' | hazl | |
10/4/2024 18:43 | A relative of mine is studying at Cambridge and she has taken an interest, whenever the company progresses further. Let's hope word gets out to the right people with deep pockets until GDR can stand on it's own two feet! | hazl | |
10/4/2024 18:41 | Unfortunately all most people care about on these bbs, is money, or lack of it. Commercialisation, is the golden word for investors and by their very nature,health companies with products that require lengthy testing, delay an investors financial gratification. I look it a bit differently these days as I expect and trust some have noticed. There seems more corruption these days in my view, where you can't even guarantee our leaders will do the right thing, pandemic and mates rates, come to mind, so little companies like these are likely the first to suffer from short termism and a colder society as people get poorer. I very much want the company to succeed, for what I hope are all the right reasons. If there was a clear income stream leading up to the confirmation of success, then that would definately help. I applaud your interest. | hazl | |
10/4/2024 18:29 | The hospitals themselves perhaps? Depends how dedicated you are. You could approach Genedrive themselves. | hazl | |
10/4/2024 18:26 | Are there any other sites / sources of information you'd recommend? | indomie1 | |
10/4/2024 18:24 | Well at least you have made a start. We all have our own specific knowledge bases. Perhaps you expect too much of a billboard especially in times like this. | hazl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions